Potential conflict of interest: There are no conflicts of interest.
Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit†
Article first published online: 10 NOV 2010
Copyright © 2010 Movement Disorder Society
Volume 26, Issue 4, pages 739–742, March 2011
How to Cite
Saccà, F., Piro, R., De Michele, G., Acquaviva, F., Antenora, A., Carlomagno, G., Cocozza, S., Denaro, A., Guacci, A., Marsili, A., Perrotta, G., Puorro, G., Cittadini, A. and Filla, A. (2011), Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. Mov. Disord., 26: 739–742. doi: 10.1002/mds.23435
- Issue published online: 19 APR 2011
- Article first published online: 10 NOV 2010
- Manuscript Accepted: 12 AUG 2010
- Manuscript Revised: 2 JUL 2010
- Manuscript Received: 13 MAY 2010
- “Associazione il cuore in un dono” Cardito, Naples, Italy
- “Associazione Italiana per la lotta alle Sindromi Atassiche (AISA) sez. Campania”, Napoli, Italy
- Janssen-Cilag SpA (Italy)
Additional Supporting Information may be found in the online version of this article.
|MDS_23435_sm_SuppFig1.tif||1404K||Supporting Information Figure 1. Serum EPO levels. Serum EPO levels at baseline and 24, 48, 96, hours and 7, 15, 30, 60 days after Epoetin alfa administration (triangle for the 600 IU/Kg dose, square for 1200 IU/Kg; n=9). Mean ± standard deviation.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.